On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Harnessing the Power of Artificial Intelligence to Improve Clinical Outcomes

Company: Predictive Oncology Inc. (POAI)
Category: Stock Spotlights

Predictive Oncology (NASDAQ: POAI), a knowledge-driven, precision-medicine company, applies its smart tumor profiling and artificial intelligence (“AI”) platform to extensive genomic and biomarker patient data sets to predict and improve clinical outcomes for cancer patients. An article discussing the company reads, “While precision medicine, sometimes referred to as personalized medicine, is a relatively new term, the idea has been around for years (http://nnw.fm/0gXRp). Defined by the U.S. National Library of Medicine as ‘an emerging approach for disease treatment and prevention that takes into account individual variability in genes, environment, and lifestyle for each person,’ the approach is gaining momentum as data sets especially in genomics have grown rapidly. Applying AI approaches to these large data sets offers the ability to more deeply analyze these data much faster and with more accurate results than previously. . . .Predictive Oncology is at the forefront of this growing trend that examines multiple factors about the patient from genomics, tumor profiles, nutrition, environmental factors, lifestyle and habits to determine a plan of action for treatment. In a recent overview (http://nnw.fm/w8W7b), POAI notes that for years, big pharma has invested tremendous resources — both financial and human — in genomics in order to understand a patient’s genome and hopefully provide more targeted treatments. However, despite the significant amount of time and money devoted to the research, success rates for such targeted therapies remain low, and adoption in clinical practice is lukewarm. It has become increasingly clear that genomics alone is not enough. . . . Enter Predictive Oncology. Competitors in the cancer field must wait at least five years to determine patient survival rates for specific treatments before they can show value in the data they have gathered. POAI, on the other hand, has vast amounts of historical data that it has been compiling for years, time-tested and proven data that can be leveraged today.”

To view the full article, visit http://nnw.fm/zXx1a

About Predictive Oncology Inc.

Predictive Oncology is an AI-driven company focused on applying artificial intelligence to personalized medicine and drug discovery. The company applies smart tumor profiling and its AI platform to extensive genomic and biomarker patient data sets to predict clinical outcomes and, most importantly, improve patient outcomes for cancer patients of today and tomorrow. Predictive Oncology currently has approximately 150,000 clinically validated cases on its molecular information platform, with more than 38,000 specific to ovarian cancer. The company’s data is highly differentiated, having both drug-response data and access to historical outcome data from patients. Predictive Oncology intends to generate additional sequence data from these tumor samples to deliver on the clear, unmet market need across the pharmaceutical industry for a multi-omic approach to new-drug development. For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork.

NetworkNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 212.418.1217